Based on the results of the present study, it is hypothesized that primary and acquired resistance to paclitaxel in ovarian cancer may be due to the activation of the Src signaling pathway, and the associated cancer cell proliferation, angiogenesis, invasion and dissemination. This evidence concerns the gene SRC and ovarian carcinoma.